VOLUME 5 , ISSUE 2 ( April-June, 2022 ) > List of Articles
JV Sabarianandh, Packia Sakaya Mercy, K Manimekalai, L Bernaitis, L Benita Mary
Keywords : COVID-19, COVID-19-associated mucormycosis (CAM), Mucormycosis
Citation Information : Sabarianandh J, Mercy PS, Manimekalai K, Bernaitis L, Mary LB. Mucormycosis in Post-COVID Patients: A Review. 2022; 5 (2):34-38.
DOI: 10.5005/jp-journals-10082-03143
License: CC BY-NC 4.0
Published Online: 25-05-2022
Copyright Statement: Copyright © 2022; The Author(s).
The mucormycetes fungus causes mucormycosis (also known as zygomycosis), a dangerous but uncommon fungal infection. Molds can be found in a variety of places. Mucormycosis is a fungus that primarily affects those who have health problems or who use medications that lower the body's ability to fight infections and sickness. It is a dangerous invasive fungal infection that can impact people who have uncontrolled diabetes, kidney failure, organ transplants, long-term steroid and immunosuppressive medicines, cirrhosis, burns, AIDS, and tumors such as lymphomas and leukemias. The researchers conducted a systematic review of a number of studies that demonstrated the presence of mucormycosis in post-COVID patients. The researchers began to observe how mucormycosis affected those who had been infected with a virus. We found nine articles on Google Scholar and the Internet using the keywords “COVID” and “mucormycosis,” describing 13 post-COVID patients infected with mucormycosis. Mucormycosis can appear in at least six different clinical syndromes, including rhino-orbito-cerebral, lung, cutaneous, gastrointestinal, disseminated, and other: pulmonary disease (three study papers with four trials each and one research report with four patients); gastrointestinal disease (one research paper with one case); and disseminated disease (one research paper with one case). Seven of the 13 patients died, according to previous study reports. According to Worldometer, coronavirus disease-2019 (COVID-19) has been reported in almost 88 million cases, with nearly 1.9 million deaths globally. Despite the fact that there are no signs of mucormycosis in COVID patients, the death rate is over 50%. The situation is really alarming. Because delayed diagnosis and inadequate treatment can lead to poor outcomes, more research is needed.
© Jaypee Brothers Medical Publishers (P) LTD.
We use cookies on this site to enhance your user experience.
By clicking any link on this page you are giving your consent for us to set cookies.